CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
23rd Annual Needham Virtual Healthcare Conference
Fireside Chat: Tuesday, April 9, 2024 at 3:45 pm ET
Location: Virtual
Chardan's 8th Annual Genetic Medicines + Cell Therapy Manufacturing Summit
Fireside Chat: Monday, April 29, 2024 at 9:30 am ET
Location: Virtual
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.23 |
| Daily Change: | 0.02 0.68 |
| Daily Volume: | 1,859,520 |
| Market Cap: | US$278.040M |
July 21, 2025 June 25, 2025 June 25, 2025 March 20, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
